Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer

ClinicalTrials.gov ID: NCT02889900

Public ClinicalTrials.gov record NCT02889900. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Single Arm, Open-label, Phase IIb Study to Assess the Efficacy and Safety of the Combination of Cediranib and Olaparib Tablets in Women With Recurrent Platinum Resistant Epithelial Ovarian Cancer, Including Fallopian Tube and/or Primary Peritoneal Cancer Who do Not Carry a Deleterious or Suspected Deleterious Germline BRCA Mutation

Study identification

NCT ID
NCT02889900
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
AstraZeneca
Industry
Enrollment
62 participants

Conditions and interventions

Interventions

  • cediranib and olaparib Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 120 Years
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 16, 2017
Primary completion
Aug 26, 2019
Completion
Mar 15, 2021
Last update posted
Mar 7, 2022

2017 – 2021

United States locations

U.S. sites
25
U.S. states
15
U.S. cities
24
Facility City State ZIP Site status
Research Site Mobile Alabama 36604
Research Site Anchorage Alaska 99508
Research Site Downey California 90241
Research Site Greenbrae California 94904
Research Site Orange California 92868
Research Site San Diego California 92123
Research Site San Francisco California 94115
Research Site West Hollywood California 90048
Research Site Miami Florida 33136
Research Site Miami Florida 33176
Research Site Orlando Florida 32804
Research Site Augusta Georgia 30901
Research Site Newnan Georgia 30265
Research Site Fort Wayne Indiana 46804
Research Site Westwood Kansas 66205
Research Site Covington Louisiana 70433
Research Site Towson Maryland 21204
Research Site Boston Massachusetts 02215
Research Site Billings Montana 59101
Research Site New York New York 10032
Research Site Rochester New York 14642
Research Site Charlotte North Carolina 28204
Research Site Winston-Salem North Carolina 27103
Research Site Knoxville Tennessee 37920
Research Site Seattle Washington 98104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02889900, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 7, 2022 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02889900 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →